tbuckley/cabot-search huggingface dataset:
On the Value of Test Meals as a Guide to Infant Feeding
Authors: R. Carter
Journal: BMJ (1910)

Then she developed a persistent nasal catarrh, from which I isolated the bacillus of Friedlander, and prepared a vaccine which did temporarily stop the rhinorrhoea, but did more harm than good.A nasal polypus was then removed, and was fol- lowed by infection of the maxillary antrum.This was drained and washed, but the other sinuses became infected one after the other.All the sinuses have now been operated upon except the sphenoidals, and now, by wearing a tiny style to drain the frontal sinus, the poor girl seems to have been given relief from this trouble.However, after each operation urethral catheteri- zation became necessary, and at the last one a cystitis due to B. coli infection was acquired in spite of every precaution.It spread up to the kidneys, causing a critical illness (February 6th, 1910).The chart commences two weeks after this had passed its acute stage, while there was still pain and tenderness in the kidneys, and much pus in the urine.Though the temperature was normal, the antitryptic index was high (7" delay).I did not dare risk the possibly injurious effect of a coli vaccine at this stage, though if one could have foreseen how obstinate the case would prove, a vaccine would have been worth the risk.As she had previously reacted very well to tuberculin (it always acted like a strong tonic) I gave her a small dose of T.R.(41)6 mg.).This and three other doses had an unmistakably good effect on all her symptoms, and also on the antitryptic index.A relapse, however, occurred, due partly to the necessity of her having another nasal polypus removed.This probably caused the big rise in the index about April 4th.The dose of coli vaccine she then had was probably slightly too large (20 million), as it produced a preliminary rise in the index and a fall delayed too long.The dose on April 20th was probably correct, as it caused a prompt and decisive fall in the index (4"), but of course one cannot generalize on such slender evidence.A vaccine appears to cause no fall of a normal index, but too large a dose would no doubt produce a riEe, so that in either case the index may afford valuable guidance.Those who are accustomed to opsonic curves must bear in mind that our object is to coax the curve down to the normal instead of trying to force the curve up, as in opsonic work.Dry cupping I found of great benefit in this and similar cases, but I could not disentangle any effect on the antitryptic index attributable to it.Urotropin, as usual in my experience of a coli urinary infec- tion, did no good, but helmitol, as usual, proved distinctly helpful.Methylene blue did no good in this case, and possibly harm.The index varied independently ef the temperature, proving much more sensitive to the vagaries of the kidneys and to the influence of vaccines. CONCLUSIONS.1.It is possible by this method to measure the anti- tryptic index with only ,'l c.cm. of serum, which is easily
Cervical Diskography: Is It Relevant?
Authors: Stanley E. Sneider
Journal: JAMA (1963)

In an effort to relate the symptoms of patients with neck injuries to roentgenographic findings in and between the cervical vetrebrae, the authors compared the results of 56 cervical diskogram studies with the corresponding hospital charts. All of the patients concerned had symptoms, and 55 had histories of previous trauma, usually of the "whiplash" variety. In only one patient had all the injected intervertebral disks been pronounced normal. The frequency of abnormal diskograms increased with increasing age. Extravasation of the injected contrast material frequently occurred on the asymptomatic side. These observations, coupled with present knowledge of the high incidence of cervical disk disease, indicate that cervical diskography has little or no relevance in attempts to elucidate the cause of the symptoms that sometimes persist after neck trauma.
Recurrence of Venous Thromboembolism after Treatment with Unfractionated Heparin
Authors: Stuart Keith Sutton
Journal: Annals of Internal Medicine (1996)

Letters1 March 1996Recurrence of Venous Thromboembolism after Treatment with Unfractionated HeparinStuart Keith Sutton, MDStuart Keith Sutton, MDHealth Services Association of Central New York Syracuse, NY 13224-1396Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-5-199603010-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The study by de Valk and colleagues [1] satisfactorily achieved the authors' stated goal of “[defining] the optimal dose of danaparoid for further clinical testing in the treatment of venous thromboembolism.” Their conclusion of superior efficacy, however, is based on a comparison with a sub-standard regimen for administering unfractionated heparin. Adequate dosing requires the use of a formal nomogram such as that of Raschke and colleagues [2]. Furthermore, therapeutic prolongation of the activated partial thromboplastin time must occur within 24 hours of the initiation of treatment [3]. The lack of an appropriate nomogram suggests that the target ...References1. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized, controlled trial. Ann Intern Med. 1995; 123:1-9. Google Scholar2. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based dosing nomogram compared with a “standard care” nomogram. Ann Intern Med. 1993; 119:874-81. Google Scholar3. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986; 315:1109-14. Google Scholar4. Lee HN, Cook DJ, Sarabia A, Hatala R, McCallum A, King D, et al. Inadequacy of intravenous heparin therapy in the initial management of venous thromboembolism. J Gen Intern Med. 1995; 10:342-5. Google Scholar5. Ansell JE. Oral anticoagulant therapy—50 years later. Arch Intern Med. 1993; 153:586-96. Google Scholar Author, Article, and Disclosure InformationAffiliations: Health Services Association of Central New York Syracuse, NY 13224-1396 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1996Volume 124, Issue 5Page: 532KeywordsAnticoagulant therapyAnticoagulantsDeep vein thrombosisHeparinInternational normalized ratioMedical servicesPartial thromboplastin timeVenous thromboembolism Issue Published: 1 March 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Ultrasound-triggered local release of lipophilic drugs from a novel polymeric ultrasound contrast agent
Authors: K. Kooiman, M.R. Böhmer, M. Emmer, H.J. Vos, C. Chlon, M. Foppen-Harteveld, M. Versluis, N. de Jong, A. van Wamel
Journal: Journal of Controlled Release (2008)
AB0228 Cardiovascular risk in ethnic minorities with rheumatoid arthritis
Authors: G. Kerr, Y. Yazici, C. Swearingen, C. Luo, L. Espinoza, Y. Sherrer, E. Treadwell, A. Mosley-Williams, R. Alamino Perez, Y. Bata, S. Dowell, A. Godoy, M. Paul
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Cardiovascular (CVD) comorbidity and mortality in rheumatoid arthritis (RA), is well documented.<sup>1</sup> Increased prevalence of the metabolic syndrome, higher disease activity, greater prednisone and less DMARD usage are established contributors. RA patients are less frequently evaluated for CVD risk factors<sup>2</sup>. Yet, ethnic minorities have a greater prevalence of CVD risk factors and events. <h3>Objectives</h3> To evaluate the CVD risk scores in ethnic minority RA patients. <h3>Methods</h3> Enrolled, consented EMRAC patients were evaluated. Data collected include socio-demographic, RA disease severity and activity-related parameters, tobacco use, prednisone and DMARD/biologic usage, and comorbidities (HTN, DM, lipidemia, CVD event). Additional data included systolic BP, total cholesterol (TC), LDL, HDL. Coronary heart disease (CHD) and non-coronary cardiovascular disease (CVD) 10-year risk SCORES<sup>3</sup> were calculated for ethnic minority subsets, and association with RA disease-related variables and treatments evaluated. CHD and CVD 10 yr-risk scores were sumarrized as continuous and dichotomozied at &gt;5%. <h3>Results</h3> 156 EMRAC patients had complete datasets for analysis. The majority were female, 142(91%), of mean age 58.1 (13.6) years, with mean disease duration 8.9 (7.8) years. 70 (45%) were Caucasian, 20 (13%) were African-American, 26 (17%) were Hispanic with 40 (26%) Other. Mean values for lipids were as follows: HDL, 64.9 (17.1) mg/dl, LDL 104(33.5) mg/dl and TC 191(39.0) mg/dl. Mean Systolic BP was 124.4(16.5) mmHg. CVD risk is summarized in Table. Dichotomizing the predicted risk score at 5%, our cohort's fatal CVD risk ranged from 14% (low risk profile) to 20% (high risk profile). However, 25% of the African-Americans had a 5% risk (low and high risk profiles) compared to Caucasians risk which ranged from 9% to 17% (low risk and high risk profile, respectively), but did not reach statistical signficance. <h3>Image/graph</h3> <h3>Conclusions</h3> EMRAC patients are at risk for fatal CVD events. While the limited sample size precluded statistical significance in ethnic differences, there is the potential for clinical relevance and our findings call for due diligence in minimizing CVD risk factors. <h3>References</h3> Meune, C. Arch Cardiovasc Dis. 2010 Desai, S. Arth. Res Ther. 2012 Peters, M. Ann. Rheum Dis, 2010 <h3>Disclosure of Interest</h3> G. Kerr Grant/research support from: EMRAC receives unrestricted grant support from Genentech, Pfizer and Bristol Myers Squibb, Y. Yazici: None Declared, C. Swearingen: None Declared, C. Luo: None Declared, L. Espinoza: None Declared, Y. Sherrer: None Declared, E. Treadwell: None Declared, A. Mosley-Williams: None Declared, R. Alamino Perez: None Declared, Y. Bata: None Declared, S. Dowell: None Declared, A. Godoy: None Declared, M. Paul: None Declared
A CASE OF PROGRESSIVE IDIOPATHIC ATROPHY OF THE SKIN.
Authors: A. RAVOGLI
Journal: JAMA (1903)

Progressive atrophy of the skin is an affection of great importance on account of the causes producing it and the conclusions which we can derive therefrom. Cases of this affection have been reported by Buchwald, Touton, Colombini, Elliott, Bronson, Pospelow, Neuman, Ohmann-Dumesnil, Popoff, Jadassohn, Unna, Krzysztal-owicz and others. In some of the cases the morbid process producing atrophy of the skin was known, in others it was perfectly obscure. From the study of all the reported cases Unna gave his classification of the atrophies of the skin as idiopathic and deuteropathic, calling idiopathic the cases where the skin is primarily affected, without progressed morbid process, and deuteropathic the cases of atrophy where the skin falls into atrophy secondarily on account of a tubercular, syphilitic or other process which has damaged its stroma. Our case belongs to the first group, the affection occurring primarily on the skin. The idiopathic atrophies
EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
Authors: Jennifer Clark, Jan Cools, D. Gary Gilliland
Journal: PLoS Medicine (2005)

Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?
Chloroquine in Hepatitis
Authors: Arnold H. Kadish
Journal: JAMA (1961)

<h3>To the Editor:—</h3> In the Questions and Answers section ofThe Journal(<b>176</b>:748 [May 27] 1961) Dr. Capps states that "it seems likely that there must be some invasion of the liver with ameba" because of the beneficial effect of chloroquine in hepatitis complicating infectious mononucleosis. Chloroquine and related agents such as hydroxychloroquine sulfate (Plaquenil) are being found useful in a number of situations, be it infectious mononucleosis, the collagen diseases, rheumatoid arthritis, or sarcoid. The beneficial effect is related to interaction of the drug with nucleoproteins, and—in ways not entirely clear—it may be helpful in the diverse conditions mentioned. This in no way makes it seem likely that there is an amebic hepatitis in infectious mononucleosis. Indeed, some degree of hepatitis is present in most cases of this illness.
TCT-226 Comparison Of Endothelial Function In The Left Main Coronary Artery And Epicardial Arterial Segments
Authors: Rishi Puri, Stephen Nicholls, Gary Liew, Danielle Brennan, Jordan Andrews, Adam Nelson, Angelo Carbone, Barbara Copus, Samir Kapadia, E. Murat Tuzcu, John Beltrame, Stephen Worthley, Matthew Worthley
Journal: Journal of the American College of Cardiology (2012)
Parathyroid Hormone–Related Protein Localization in Breast Cancers Predict Improved Prognosis
Authors: Michael A. Henderson, Janine A. Danks, John L. Slavin, Graham B. Byrnes, Peter F.M. Choong, John B. Spillane, John L. Hopper, T. John Martin
Journal: Cancer Research (2006)

Abstract In a prospective study of 526 consecutive patients with operable breast cancer, the significance of positive parathyroid hormone–related protein (PTHrP) staining by immunohistology has been evaluated for a median of 10-year follow-up. Improved survival was observed for the 79% of tumors which stained positively for PTHrP [estimated univariate hazard ratio, 0.43; 95% confidence interval (95% CI), 0.30-0.62; P &amp;lt; 0.001]. Adjustments for N stage, progesterone receptor status, and log tumor size changed this estimate only slightly to 0.47 (95% CI, 0.63-0.69; P = 0.001). Patients with PTHrP-positive primary tumors were less likely to develop bone metastases (hazard ratio, 0.63; 95% CI, 0.41-0.98; P = 0.04). PTHrP status was associated with estrogen receptor (P = 0.01), progesterone receptor (P = 0.03), and menopausal status (P = 0.006) but was not significantly associated with tumor size, vascular invasion, tumor grade, or patient age. Of 19 patients requiring surgery for bone metastases, the primary cancers were PTHrP negative in seven, all but one of whom had PTHrP-positive bone metastases. All 12 patients with PTHrP-positive primary cancers also had positive bone metastases. We conclude that increased production of PTHrP by breast cancers confers on them a less invasive phenotype, an effect distinct from the bone resorption–stimulating action that favors bone metastasis. It is likely that the latter property is influenced by factors in the bone microenvironment. (Cancer Res 2006; 66(4): 2250-6)
Toxic effects of silver-silver chloride electrodes on vascular smooth muscle.
Authors: W F Jackson, B R Duling
Journal: Circulation Research (1983)

We found that silver, either as silver metal or silver chloride, exerted toxic effects on the smooth muscle of isolated cannulated hamster cheek pouch arterioles. Silver initially stimulated the smooth muscle, producing a marked vasoconstriction. The vessels then dilated back to control diameters. Once the arterioles began to dilate, they became refractory to norepinephrine or potassium stimulation. We caution the use of silver in the presence of smooth muscle, especially when tissue mass is small or free protein concentration is low.
Potassium Tolerance in Sickle-Cell Hemoglobinopathy
Authors: PAUL MITNICK
Journal: Annals of Internal Medicine (1979)

Letters1 August 1979Potassium Tolerance in Sickle-Cell HemoglobinopathyPAUL MITNICK, M.D., RICHARD STERNS, M.D., MALCOLM COX, M.D.PAUL MITNICK, M.D.Search for more papers by this author, RICHARD STERNS, M.D.Search for more papers by this author, MALCOLM COX, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-91-2-319 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: De Fronzo and associates in the March 1979 issue (1) have described a K+ secretory defect in six patients with sickle-cell hemoglobinopathy but hyperkalemia (even during acute and chronic potassium loading) was notably absent. However, these authors made note of an abstract (2) describing hyperkalemia in a patient with sickle-cell hemoglobinopathy and commented that they have seen a chronically hyperkalemic patient with HbSS disease. We have recently studied a patient with documented HbSS disease who developed life-threatening hyperkalemia while receiving only modest amounts of potassium.A 25-year-old black woman underwent cesarean section at 36 weeks with uncomplicated...References1. DEFRONZO R, TAUFIELD P, BLACK H, MCPHEDRAN P, and COOKE C. Impaired renal tubular potassium secretion in sickle cell disease. Ann Intern Med. 1979;90:310-6. LinkGoogle Scholar2. ROSEMAN M, SEHY J, ARRUDA J, and KURTZMAN N. Studies on the mechanism of hyperkalemic distal renal tubular acidosis (dRTA): gradient type dRTA in SC hemoglobinopathy. In: Proceedings of the Tenth Meeting of the American Society of Nephrology. Washington, D.C.: American Society of Nephrology; 1977:21. Abstract. Google Scholar3. EHRLICH E and LINDHEIMER M. Effect of administered mineralocorticoids or ACTH in pregnant women: attenuation of kaliuretic influence of mineralocorticoids during pregnancy. J Clin Invest. 1972;51:1301-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PAUL MITNICK, M.D.; RICHARD STERNS, M.D.; MALCOLM COX, M.D.Affiliations: Hospital of the University of Pennsylvania Philadelphia Veterans Administration Hospital Philadelphia, Pa 19104 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byVitamin-K-Resorptions- und Verwertungsstörungen, Hämostasedefekte bei Lebererkrankungen 1 August 1979Volume 91, Issue 2Page: 319-320KeywordsCesarean sectionHemoglobinopathiesPotassium ePublished: 1 December 2008 Issue Published: 1 August 1979 PDF downloadLoading ...
Effects of Cholesterol Lowering on the Progression of Coronary Atherosclerosis in Women
Authors: David Waters, Lyall Higginson, Peter Gladstone, Stephen J. Boccuzzi, Thomas Cook, Jacques Lespérance
Journal: Circulation (1995)

Background Although coronary disease is the leading cause of death in women and its clinical features differ from those in men, very few women have been included in angiographic trials of cholesterol lowering. Methods and Results Sixty-two women with diffuse but not necessarily severe coronary atherosclerosis documented on a recent angiogram and with fasting serum cholesterol between 220 and 300 mg/dL were enrolled in a double-blind, placebo-controlled trial. More than one half had a history of hypertension, approximately one quarter were diabetics, and one third were current smokers. All women received dietary counseling. Lovastatin or placebo was begun at 20 mg/d and was titrated if necessary to 40 and then to 80 mg during the first 16 weeks to attain a fasting LDL cholesterol ≤130 mg/dL. The mean lovastatin dose was 34 mg/d. Total and LDL cholesterol decreased by 24% and 32%, respectively, in lovastatin-treated women but by &lt;3% in women receiving placebo. Coronary arteriography was repeated after 2 years in 54 women (87%), and their 394 lesions were measured “blindly” on pairs of film with an automated computerized quantitative system. Progression, defined as a worsening in minimum diameter of one or more stenoses by ≥0.4 mm, occurred in 7 of 25 lovastatin-treated women and 17 of 29 placebo-treated women (28% versus 59%, P =.031). New coronary lesions developed in 1 lovastatin-treated woman and 13 placebo-treated women (4% versus 45%, P &lt;.001). The outcome for each of the angiographic end points was not significantly different between the women and the 245 men who completed the trial. Conclusions Lovastatin slows the progression of coronary atherosclerosis and prevents the development of new coronary lesions in women.
Case 40-1967
Authors: Lot B. Page, Richard B. Cohen
Journal: New England Journal of Medicine (1967)

Presentation of CaseA sixty-six-year-old man was admitted to the hospital because of pain in the abdomen and back.On the morning of admission he experienced the sudden onset of pain in the left lower quadrant of the abdomen as well as pain in the lower portion of the back, with radiation to the hips.On examination three years before entry the blood pressure was 190 systolic, 115 diastolic. He complained of occasional aches in the calves at night. An intravenous pyelographic examination was negative. The creatinine was 1.4 mg. per 100 ml. With methyldopa and chlorothiazide therapy the diastolic . . .
COMPARISON OF CONTRAST-INDUCED NEPHROPATHY RISK PREDICTION MODELS WITH OR WITHOUT POST-PROCEDRUAL VARIABLES
Authors: Taku Inohara, Shun Kohsaka, Hiroaki Miyata, Ikuko Ueda, Kentaro Hayashida, Yuichiro Maekawa, Akio Kawamura, Keiichi Fukuda
Journal: Journal of the American College of Cardiology (2014)
Saunders Infection Control Reference Service
Authors: Paul O'Keefe
Journal: Annals of Internal Medicine (1998)

Medical Writings15 April 1998Saunders Infection Control Reference ServicePaul O'Keefe, MD and Sandra M. Blake VonBehren, RN, MSPaul O'Keefe, MDLoyola University Medical Center, Maywood, IllinoisSearch for more papers by this author and Sandra M. Blake VonBehren, RN, MSLoyola University Medical Center, Maywood, IllinoisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-8-199804150-00037 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Abrutyn E, Goldmann DA, Scheckler WE; eds. 1282 pages. Philadelphia: WB Saunders; 1998. $295.00. ISBN 0721664431. Order phone 800-545-2522.Field of medicine: Epidemiology and infection control.Format: Hardcover book.Audience: Hospital and health care epidemiologists, infection control practitioners, health system and hospital administrators, managers of engineering and facilities departments, and quality improvement managers.Purpose: To publish in one book the many guidelines used in infection control and to recommend strategies for implementation.Content: The authors of the chapters have gathered the guidelines used in infection control from various organizations and publications. Topics covered include the infection control program, locations at ... Author, Article, and Disclosure InformationAffiliations: Loyola University Medical Center, Maywood, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1998Volume 128, Issue 8Page: 700KeywordsEpidemiologyInternetMedical servicesNosocomial infectionsPathogensPneumoniaQuality improvementTuberculosisUrinary tract infections Issue Published: 15 April 1998 CopyrightCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Fondaparinux for Symptomatic Pulmonary Embolism
Authors: Alan F. Hofmann
Journal: New England Journal of Medicine (2004)

To the Editor: The summary of the article on fondaparinux for symptomatic pulmonary embolism in This Week in the Journal (Oct. 30 issue)1 shows the chemical structure of fondaparinux and refers to it as a pentasaccharide. Although it is true that fondaparinux has a pentasaccharide skeleton, its pharmacodynamic activity as a thrombin inhibitor is surely attributable to the eight sulfate groups that make it a polyanion, analogous to heparin. These sulfate groups are shown clearly in the figure accompanying the summary. It would be preferable to describe fondaparinux as a sulfated pentasaccharide or as a pentasaccharide polysulfate.